Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on OXFORD BIOMEDICA PLC. We currently have 29 research reports from 4 professional analysts.
|24Feb17 09:36||RNS||Director Dealings|
|01Feb17 10:09||RNS||Total Voting Rights|
|25Jan17 09:02||RNS||Director/PDMR Shareholding|
|24Jan17 16:34||RNS||Director Dealings / Market Share Purchase|
|24Jan17 09:31||RNS||Director/PDMR Shareholding|
|23Jan17 09:57||RNS||Director/PDMR Shareholding|
|03Jan17 09:30||RNS||Block Listing Return|
Frequency of research reports
Research reports on
OXFORD BIOMEDICA PLC
OXFORD BIOMEDICA PLC
Encouraging CTL019 data in paediatric r/r B-ALL
05 Dec 16
At ASH this weekend, Novartis presented data from its global registration trial (ELIANA) of CTL019 in relapsed/refractory (r/r) paediatric and young adults with B-cell acute lymphoblastic leukaemia (B-ALL). In one of the largest CAR-T trials to date, 41 out of 50 (82%) treated patients achieved a complete remission or complete remission with incomplete blood count recovery. These positive results have prompted Novartis to reaffirm its timelines for filing in B-ALL, with a submission to the FDA expected in early 2017 and to the EMA later in 2017. This data, along with the restated timelines, reinforce our forecasts for Oxford BioMedica (OXB), which manufactures and supplies the vectors that are utilised in CTL019. We value OXB at £173m (6.2p/share).
N+1 Singer - Oxford BioMedica - Positive CTL019 data
05 Dec 16
The positive CTL019 trial results in ALL (acute lymphoblastic leukaemia) announced by Novartis at the weekend is encouraging. Oxford BioMedica has been manufacturing lentivector material for Novartis since the agreement was first established in 2013. Oxford BioMedica is eligible to royalties on CTL019 product sales. Filing of CTL019 with the FDA remains on track for early 2017. Our forecasts currently assume the product is launched in 2017 and we look forward to additional updates in due course. We remain at Hold.
Orchard deal adds to growing revenue stream
02 Dec 16
Oxford BioMedica’s (OXB’s) recently announced strategic alliance with Orchard Therapeutics further underpins the value the wider cell therapy market sees in its in-house capabilities. OXB will develop and supply lentiviral vectors to Orchard for use in primary immune deficiency and inherited metabolic disorders. OXB has received a 1.95% equity stake in Orchard and will receive royalties on future of products covered by the deal. Our valuation for OXB remains unchanged at £173m (6.2p/share).
N+1 Singer - Morning Song 29-11-2016
29 Nov 16
Bagir Group (BAGR LN) Successful delivery of 1st Ethiopian orders | easyHotel (EZH LN) Reassuring finals & tenor | Eckoh (ECK LN) In line interims, US secure payments gathers pace | Ergomed (ERGO LN) PharmInvent acquisition complements PrimeVigilance | Gooch & Housego (GHH LN) Good FY16 growth, forecast to increase in FY17 | ITE Group (ITE LN) No change in trading conditions | MySale Group (MYSL LN) Positive start to year drives upgrades | Oxford BioMedica (OXB LN) Strategic alliance with Orchard Therapeutics | Vp (VP/ LN) Excellent interims, outperforming again
Balancing risk to optimise reward
06 Nov 16
Oxford BioMedica is a leader in lentivirus based gene technology and ongoing manufacturing deals (CTL019 with Novartis) underpin the valuation. We expect pipeline focus in the near term as OXB aims to optimise development via out-licensing or externally funded SPVs. The newly announced strategy takes into account the balance of risk versus reward for stakeholders (against the backdrop of the significant financial resources required over the next two to three years to advance OXB’s value, driving assets to the next stage). The recent net £10m equity fund-raising will extend the current cash runway beyond 2017 due to reduced R&D expenditure; further funding and value may arise from additional manufacturing or IP licensing deals. We value OXB at £173m.
N+1 Singer - Morning Song 14-10-2016
14 Oct 16
Applied Graphene Materials (AGM LN) First production order | Carclo (CAR LN) Complementary acquisition; trading in line | Grafenia (GRA LN) Conditions challenging; trading improving | Oxford BioMedica (OXB LN) Forecasts updated, upgrade to Hold | Thin Film Electronics ASA (THIN NO) Acquisition of high volume manufacturing capability is milestone event
Interim results – adhering to international growth strategy
23 Feb 17
Interim results showed a strong performance for Tristel, 6% ahead of its AGM statement on 12 December at which it indicated adjusted pre-tax profits to be no less than £1.6m. Revenues increased by 22% (16% at constant exchange rates – CER or 12% CER excluding the impact of the Australian acquisition) and adjusted pre-tax profits were up 15% to £1.71m. Despite the strong half, we leave our full-year forecasts unchanged, given FX uncertainty and a one-off stocking order in H1 from the NHS, although at current FX rates the risk to our forecasts is considered to be to the upside. However, we raise our target price by 10% to 165p to reflect the solid progress as well as rolling forward our multiples to calendar-adjusted 2017.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
Consistently strong growth at a sensible price
24 Feb 17
In “Alice in Wonderland”, Lewis Carroll tells the story of a girl, who falls through a rabbit hole into a world populated by peculiar, anthropomorphic creatures. Here, Alice crosses swords with the Queen of Hearts, meets the Cheshire Cat and is invited to the "Mad Hatters” tea party, which she subsequently discovers is “stupid”.
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals
£21m equity raise to accelerate growth
22 Feb 17
Blindly following what others do is often a recipe for disaster. However, when an army of ‘super smart’ fund managers snap-up a big holding in a rapidly expanding small-cap that owns ‘disruptive’ technology addressing multi-$billion markets, then it is usually worth taking note. This is exactly what has happened at Kromek, a next generation radiation detection firm. Having just successfully completed its oversubscribed £20m placing and £1m open offer at 20p/share - supported by esteemed investors such as Gervais Williams at Miton (largest shareholder at 19.0%) and Katie Potts (Herald 5.35%), as well as several others such as Schroders (5.0%) and Killik (4.1%).
N+1 Singer - Anpario - Feed for growth
24 Feb 17
Anpario’s natural animal feed additive product offering is well placed to benefit from the increasing demand for animal protein and tightening regulations around antibiotic use as growth promoters. The group is in a transition phase, building strong commercial relationships with end users, which we believe should benefit the margin. Anpario’s geographical diversity is a key positive and with a strong balance sheet there is potential for acquisitive as well as organic growth. We initiate coverage with a 354p Target Price and a Buy recommendation ahead of FY results on 8th March.